Treatment of multiple sclerosis with DDS drug targeting to autoantigen-recognizing immune cells

Abstract

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system and the use of some disease-modifying drugs (DMDs) to control the neurodegenerative symptoms and to reduce the relapse rate has become the mainstream approach for clinical treatment of MS. Herein, I review the clinically-used DMDs in Japan and recent studies for the development of DDS drugs to treat MS. Then, I explain a targeting DDS with immune antigen-modified liposome for the treatment of immune diseases and finally introduce my recent research on the development of autoantigen-modified liposomal drug for the treatment of MS.